Literature DB >> 11135574

On guard--activating NK cell receptors.

L L Lanier1.   

Abstract

Although natural killer (NK) cells are known to preferentially kill cells that lack major histocompatibility complex class I antigens, we do not know what signals the attack of these targets. Several membrane receptors have recently been implicated in this process and include molecules with immunoreceptor tyrosine-based activation motifs (ITAM) and motifs that bind phosphoinositide-3 kinase (PI3K). Evidence is emerging that NK cells may use a combination of several receptors and signaling pathways to protect the host against infection and possibly against malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135574     DOI: 10.1038/83130

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  82 in total

1.  HLA-Cw7 zygosity affects the size of a subset of CD158b+ natural killer cells.

Authors:  Zaheed Husain; Edward Levitan; Charles E Larsen; Nadeem M Mirza; Souhad Younes; Edmond J Yunis; Chester A Alper; Devendra P Dubey
Journal:  J Clin Immunol       Date:  2002-01       Impact factor: 8.317

Review 2.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

3.  Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

Authors:  Philippe Le Bouteiller; Aliz Barakonyi; Jérome Giustiniani; Françoise Lenfant; Anne Marie-Cardine; Maryse Aguerre-Girr; Magali Rabot; Ivan Hilgert; Fathia Mami-Chouaib; Julie Tabiasco; Laurence Boumsell; Armand Bensussan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

4.  MHC-dependent and -independent modulation of endogenous Ly49 receptors on NK1.1+ T lymphocytes directed by T-cell receptor type.

Authors:  Markus Sköld; Martin Stenström; Stephane Sidobre; Petter Höglund; Mitchell Kronenberg; Susanna Cardell
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

5.  Ly49Q, a member of the Ly49 family that is selectively expressed on myeloid lineage cells and involved in regulation of cytoskeletal architecture.

Authors:  Noriko Toyama-Sorimachi; Yusuke Tsujimura; Mikako Maruya; Atsuko Onoda; Toshiyuki Kubota; Shigeo Koyasu; Kayo Inaba; Hajime Karasuyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

6.  Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption.

Authors:  Yoshiko Mizukawa; Yoshimi Yamazaki; Yuichi Teraki; Jun Hayakawa; Kazuhito Hayakawa; Hideko Nuriya; Michinori Kohara; Tetsuo Shiohara
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

7.  Exclusion of lipid rafts and decreased mobility of CD94/NKG2A receptors at the inhibitory NK cell synapse.

Authors:  Tolib B Sanni; Madhan Masilamani; Juraj Kabat; John E Coligan; Francisco Borrego
Journal:  Mol Biol Cell       Date:  2004-05-07       Impact factor: 4.138

8.  Identification of lectin-like receptors expressed by antigen presenting cells and neutrophils and their mapping to a novel gene complex.

Authors:  Line Mari Flornes; Yenan T Bryceson; Anne Spurkland; Johnny C Lorentzen; Erik Dissen; Sigbjørn Fossum
Journal:  Immunogenetics       Date:  2004-09-11       Impact factor: 2.846

9.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

10.  Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.

Authors:  G S D Reid; S Bharya; H-G Klingemann; K R Schultz
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.